[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Merritt MA, Green AC, Nagle CM, Webb PM, Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group: Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer; 2008 Jan 1;122(1):170-6
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.
  • Chronic inflammation has been proposed as the possible causal mechanism that explains the observed association between certain risk factors, such as the use of talcum powder (talc) in the pelvic region and epithelial ovarian cancer.
  • To address this issue we evaluated the potential role of chronic local ovarian inflammation in the development of the major subtypes of epithelial ovarian cancer.
  • Factors potentially linked to ovarian inflammation were examined in an Australia-wide case-control study comprising 1,576 women with invasive and low malignant potential (LMP) ovarian tumours and 1,509 population-based controls.
  • We confirmed a statistically significant increase in ovarian cancer risk associated with use of talc in the pelvic region (adjusted odds ratio 1.17, 95% CI: 1.01-1.36) that was strongest for the serous and endometrioid subtypes although the latter was not statistically significant (adjusted odds ratios 1.21, 95% CI 1.03-1.44 and 1.18, 95% CI 0.81-1.70, respectively).
  • Other factors potentially associated with ovarian inflammation (pelvic inflammatory disease, human papilloma virus infection and mumps) were not associated with risk but, like others, we found an increased risk of endometrioid and clear cell ovarian cancer only among women with a history of endometriosis.
  • Regular use of aspirin and other nonsteroidal anti-inflammatory drugs was inversely associated with risk of LMP mucinous ovarian tumours only.
  • We conclude that on balance chronic inflammation does not play a major role in the development of ovarian cancer.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Ovarian Neoplasms / epidemiology. Pelvic Inflammatory Disease / epidemiology. Talc / administration & dosage
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / epidemiology. Adolescent. Adult. Aged. Aspirin / administration & dosage. Australia / epidemiology. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / epidemiology. Case-Control Studies. Chronic Disease. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Risk Factors

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pelvic Inflammatory Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TALC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17721999.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 14807-96-6 / Talc; R16CO5Y76E / Aspirin
  •  go-up   go-down


2. Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B: Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer; 2005 Jun 1;103(11):2313-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
  • BACKGROUND: The nucleotide excision repair (NER) proteins repair DNA adducts due to xenobiotics and cancer chemotherapy.
  • The authors hypothesized that expression of the NER protein xeroderma pigmentosum A (XPA) would be reduced in a clinically significant fashion in metastatic ovarian carcinoma.
  • METHODS: Malignant effusion specimens were studied so that there was a uniform metastatic ovarian carcinoma population for study.
  • Patients in the latter group received platinum-based chemotherapy.
  • XPA expression did not correlate with treatment status, effusion site, International Federation of Gynecology and Obstetrics stage, histologic grade, or the extent of residual disease.
  • More effusion tumor cells from patients with a complete response to chemotherapy expressed XPA compared with those with a partial or no response (P = 0.03, chi(2) test).
  • Patients with recurrent disease with XPA expressed in > 25% of tumor cells had better progression-free survival (PFS) by univariate analysis (median = 0 vs. 11 months, P < 0.001; 95% confidence interval [CI], 1-5, 8-14) and overall survival (OS; median = 24 vs. 34 months, P = 0.04; 95% CI, 17-31, 24-44).
  • CONCLUSIONS: The results of the current study showed that XPA was widely expressed in metastatic ovarian carcinoma effusion specimens and in the cells of the effusion microenvironment.
  • Paradoxically, XPA expression was associated with better response to chemotherapy and predicted better PFS and OS.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Cisplatin / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Recurrence, Local / metabolism. Prognosis. Survival Rate. Xeroderma Pigmentosum Group A Protein

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844177.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / XPA protein, human; 0 / Xeroderma Pigmentosum Group A Protein; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC, Gynecologic Oncology Group: Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer; 2008 May 15;112(10):2202-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
  • BACKGROUND: The purpose was to identify the factors predictive of recurrence and survival in patients with high-risk (stage I, grade 3; stage IC, stage II, or clear cell) epithelial ovarian cancer after adjuvant therapy.
  • METHODS: Data was extracted from patients who underwent primary surgery followed by adjuvant therapy in 2 randomized trials by the Gynecologic Oncology Group (Protocols 95 and 157).
  • On multivariate analysis, older age, higher stage, higher grade, and malignant cytology were independent prognostic factors predictive for recurrence and poorer survival.
  • CONCLUSIONS: Age, stage, grade, and cytology are important prognostic factors in high-risk early-stage epithelial ovarian cancer.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18348296.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA27469; United States / NCI NIH HHS / CA / CA37517
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. McCluggage WG, Strand K, Abdulkadir A: Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer; 2002 Jan-Feb;12(1):62-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors.
  • Metallothioneins (MTs) are a group of low-molecular-weight proteins that are overexpressed in a variety of human neoplasms and are related to differentiation and prognosis in some tumor types.
  • This study investigated immunohistochemically detectable metallothionein expression in benign and malignant ovarian surface epithelial tumors of serous, mucinous, and endometrioid types.
  • Of the malignant tumors, MT expression was found in 68% of endometrioid, 56% of mucinous, and 52% of serous neoplasms.
  • The overexpression of MT in malignant as opposed to benign ovarian surface epithelial tumors may suggest a role in tumorigenesis.
  • Whether high MT expression is an independent prognostic factor and increased expression indicates chemotherapy resistance in ovarian cancer, as has been previously suggested, should be determined by further studies.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Endometrioid / chemistry. Cystadenocarcinoma, Serous / chemistry. Cystadenoma, Mucinous / chemistry. Cystadenoma, Serous / chemistry. Metallothionein / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Cell Differentiation. Female. Humans. Immunoenzyme Techniques. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11860537.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9038-94-2 / Metallothionein
  •  go-up   go-down


5. Kolosov AE, Novichkov EV: [Morphometrical and immunohistochemical criteria of prognosis in patients with serous and mucinous ovarian carcinoma]. Arkh Patol; 2003 Sep-Oct;65(5):29-32
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphometrical and immunohistochemical criteria of prognosis in patients with serous and mucinous ovarian carcinoma].
  • The aim of the study was to investigate the prognostic value of morphometrical features and expression of receptors to progesterone in malignant epithelial ovarian tumours.
  • Surgical biopsy materials of 92 patients with serous and mucinous ovarian cancer were investigated.
  • Tissues stained by hematoxilin and eosin were studied.
  • It was found that cytomorphometrical features vary in ovarian cancer with different histological structures and the level of differentiation of tumour, and can be used as prognostic factors.
  • In this group of patients 3-year survival reached almost 100% indicating the efficiency of hormonotherapy and chemotherapy.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cell Nucleus / pathology. Disease-Free Survival. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Prognosis. Receptors, Progesterone / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14664145.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Receptors, Progesterone
  •  go-up   go-down


6. Salomon LJ, Lhommé C, Pautier P, Duvillard P, Morice P: Safety of simple cystectomy in patients with unilateral mucinous borderline tumors. Fertil Steril; 2006 May;85(5):1510.e1-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of simple cystectomy in patients with unilateral mucinous borderline tumors.
  • OBJECTIVE: To report on ovarian carcinoma development after cystectomy for a borderline mucinous ovarian tumor.
  • PATIENT(S): One patient who developed recurrence in the form of an invasive ovarian carcinoma after simple cystectomy for a borderline mucinous ovarian tumor.
  • Histological examination revealed a borderline mucinous ovarian tumor.
  • No additional treatment was prescribed.
  • Two years later, the patient relapsed with a malignant mucinous ovarian carcinoma.
  • She underwent surgical resection and staging, including hysterectomy, bilateral adnexectomy, omentectomy, and pelvic and para-aortic lymphadenectomy, and platinum-based chemotherapy.
  • CONCLUSION(S): Recurrence in the form of invasive ovarian carcinoma may occur in the same ovary after cystectomy in cases of borderline mucinous ovarian tumor.
  • Such treatment enables preservation of reproductive potential and reduces the risk of developing invasive carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Cystectomy / adverse effects. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / prevention & control. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647380.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F: Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer; 2004 May 10;109(6):926-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
  • We evaluated whether tracer FDG uptake, quantified as an SUV by PET in ovarian epithelial tumors, correlates with clinical stage, tumor grade, cell proliferation and glucose metabolism, all of which are biomarkers for response to chemotherapy, prognosis and overall survival in ovarian cancer patients.
  • Seventeen patients suspected of having ovarian cancer by physical examination, tumor marker analysis and anatomic imaging (such as sonography, CT and/or MRI) underwent whole-body FDG-PET within the 2 weeks prior to surgery.
  • Seventeen epithelial ovarian tumor specimens (13 malignant tumors, 5 at stage I, 2 at stage II, 6 at stage III; 2 borderline tumors; and 2 benign lesions) were available for pathologic evaluation.
  • Therefore, glucose consumption, as determined by analysis of SUVs in FDG-PET, may be a noninvasive biomarker for ovarian epithelial tumors.
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Ki-67 Antigen / metabolism. Monosaccharide Transport Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radionuclide imaging. Biomarkers, Tumor. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radionuclide imaging. Cell Division. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radionuclide imaging. Female. Glucose / metabolism. Glucose Transporter Type 1. Humans. Neoplasm Staging. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15027127.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Ki-67 Antigen; 0 / Monosaccharide Transport Proteins; 0 / Radiopharmaceuticals; 0 / SLC2A1 protein, human; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  •  go-up   go-down


8. Chang WC, Sheu BC, Lin MC, Chow SN, Huang SC: Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):549-53
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report.
  • Epithelial ovarian tumors of borderline malignancy are tumors with histologic features and biologic behavior between benign and frankly malignant epithelial ovarian neoplasms.
  • Here, we present a 35-year-old patient with carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian tumor of borderline malignancy.
  • Total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, and omentectomy were performed, and the frozen pathology during operation showed mucinous tumor of borderline malignancy of left ovary on April 18, 2002.
  • The patient was followed at our outpatient department for 19 months after operation and was free of the disease without any adjuvant chemotherapy.
  • It is difficult to determine whether intestinal-type borderline mucinous tumors with intraepithelial carcinoma are associated with a worse prognosis compared with those with epithelial atypia alone due to disparate results in the published literature.
  • In contrast, most patients with mural nodules of anaplastic carcinoma have had a malignant, often rapid, course.
  • However, too few cases of carcinosarcoma-like mural nodule in mucinous tumor have been published to warrant a conclusion regarding their prognosis.
  • [MeSH-major] Carcinosarcoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882184.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Kikkawa F, Nawa A, Kajiyama H, Shibata K, Ino K, Nomura S: Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol; 2006 Oct;103(1):171-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and prognosis of mucinous tumors of the ovary.
  • OBJECTIVE: Ovarian mucinous tumors consist of benign, borderline, and carcinomatous tumor, but the clinical characteristics of these 3 types have not been investigated in detail.
  • In this study, we compared the clinical characteristics and prognosis among these 3 types of mucinous tumors.
  • METHODS: One hundred sixty-one patients with mucinous cystadenocarcinoma and 143 patients with mucinous borderline tumor were registered between 1986 and 2003.
  • All patients were reviewed by two pathologists, then the mixed type and cases showing other organized malignant tumors were excluded from this study.
  • Patients with mucinous carcinoma staged Ib or more were treated postoperatively with 6 cycles of platinum-based chemotherapy.
  • RESULTS: Mean patient ages were 43.9, 44.7, and 49.7 years in patients with benign, borderline, carcinomatous tumor, respectively.
  • The ratio of early stage (I, II) to advanced stage (III, IV) was significantly lower in carcinoma than in borderline tumor.
  • The levels of tumor markers tended to increase with the level of malignancy.
  • In borderline tumor, 5 patients died of disease, and all of these patients had stage III disease with residual tumor after the initial surgery.
  • Patients with borderline tumor showed significantly better prognosis than those with carcinoma; however, there were no significant differences in prognosis between borderline tumor and carcinoma in patients with stage III tumor or residual tumor.
  • CONCLUSIONS: In mucinous tumors, measurement of CA72-4 is recommended to distinguish malignant from benign tumors.
  • Even in borderline tumor, patients with residual tumor showed a poorer prognosis than carcinoma, suggesting that complete resection is necessary for a good prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546243.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Zhang J, Chen AP, Wang B, Zhao SP, Liu LZ, Dai SZ: [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer]. Ai Zheng; 2008 Dec;27(12):1331-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
  • BACKGROUND & OBJECTIVE: Abnormal expression and activation of epidermal growth factor receptor (EGFR), which is closely related to the recurrence and poor prognosis of ovarian cancer, can promote chemotherapy resistance of tumor cells.
  • Lung resistance protein (LRP), a multidrug resistance protein causing platinum-resistance, is an independent factor in predicting chemotherapy sensitivity to ovarian cancer.
  • This study was to explore the correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer.
  • METHODS: Expressions of EGFR and LRP in 76 specimens of ovarian malignant tumor, nine borderline tumor, 17 benign tumor and 15 normal ovary were studied using immunohistochemistry.
  • Patients with ovarian cancer were followed up.
  • Correlations of EGFR and LRP to chemotherapy efficacy and survival time of patients with ovarian cancer after operation were analyzed.
  • RESULTS: The positive rates of EGFR and LRP in malignant specimens (73.68% and 71.79%) were significantly higher than those in normal and benign ones (P <0.01).
  • EGFR was highly expressed in ovarian cancer patients at late stage (III-IV), with poor differentiation and ascites (P <0.05).
  • The short-term efficacy rates of ovarian cancer were lower in patients with positive expressions of EGFR and LRP (57.14% and 53.70%) than in those with negative expressions (P<0.05).
  • The positive rates of EGFR and LRP were significant higher in patients with chemotherapy resistance (92.86% and 85.71%) than in those sensitive to chemotherapy (P<0.05).
  • The three-year survival rate of ovarian cancer patients was 53.00%.
  • Patients with positive EGFR and LRP and poor short-term efficacy after chemotherapy had short survival time (P<0.01).
  • CONCLUSION: The expression of EGFR and LRP could be used to predict chemotherapy resistance and prognosis of ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Drug Resistance, Neoplasm. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / pharmacology. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080004.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Stankovic Z, Djuricic S, Djukic M, Jovanovic D, Vasiljevic M: Epithelial ovarian tumors and CA125 in premenarchal girls. Eur J Gynaecol Oncol; 2006;27(6):597-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial ovarian tumors and CA125 in premenarchal girls.
  • PURPOSE: This is a review of our 18-year experience with premenarchal girls with epithelial ovarian tumors.
  • METHODS: Analysis of premenarchal patients with resected or biopsied ovarian masses from 1988 to 2005 was performed.
  • Patient age, clinical presentation, operative procedures, histologic type of tumor, treatment and outcome were obtained.
  • RESULTS: Six premenarchal girls (aged from 6 to 14 years) were surgically treated for epithelial tumors, representing 13% of all ovarian tumors at this age.
  • Histological findings revealed cystadenoma in four girls, one with a mucinous borderline tumor and one with undifferentiated carcinoma.
  • Tumor volume was higher than 400 cm3 in four girls.
  • Sensitivity, specificity and positive predictive value of CA125 level for ovarian malignant epithelial tumors were 0.50, 0.50, and 0.33, respectively.
  • The premenarchal girl with undifferentiated carcinoma in Stage III died after six months in spite of chemotherapy.
  • CONCLUSION: Ovarian epithelial tumors in premenarchal girls show important growth potential and a relatively high malignancy rate with great influence of borderline neoplasms.
  • CA125 is a tumor marker with low sensitivity and specificity for detection of epithelial ovarian malignancy in this age group.
  • [MeSH-major] CA-125 Antigen / blood. Carcinoma / blood. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenoma, Serous / diagnosis. Ovarian Neoplasms / blood
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / blood. Child. Female. Humans. Menarche. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290590.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


12. Hauptmann S: [Differential diagnosis of ovarian metastases]. Pathologe; 2007 May;28(3):215-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis of ovarian metastases].
  • Ovarian metastases comprise 7-10% of all malignant ovarian tumors.
  • The detection of ovarian metastases is difficult because primary ovarian tumors are a morphologically very heterogeneous group, and metastases can simulate an primary ovarian tumor perfectly.
  • A correct diagnosis, however, is most important in order to avoid an unnecessary and ineffective chemotherapy.
  • Therefore, every morphologically unusual ovarian tumor should raise doubts.
  • In addition, mucinous and endometrioid tumors may also be metastatic in nature.
  • [MeSH-major] Neoplasm Metastasis / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Incidence. Mutation. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):1-10 [12502922.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):19-25 [15389251.001]
  • [Cites] Diagn Mol Pathol. 2001 Jun;10(2):116-22 [11385321.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jul;16(3):245-9 [9421090.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):805-15 [9669343.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):421-8 [12055677.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S99-111 [15492758.001]
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):323-7 [9988794.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):852-5 [7543441.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):748-56 [2764222.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):225-32 [6263118.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):178-86 [12548163.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1143-55 [6198065.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Mod Pathol. 1996 Apr;9(4):426-9 [8729984.001]
  • [Cites] J Pathol. 1997 Aug;182(4):385-91 [9306958.001]
  • [Cites] Int J Gynecol Pathol. 2004 Apr;23(2):97-9 [15084836.001]
  • [Cites] Cancer. 1982 Jul 1;50(1):163-70 [7083121.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):281-94 [15725796.001]
  • [Cites] Am J Surg Pathol. 1991 May;15(5):415-29 [2035736.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3028-31 [10397237.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jan;24(1):67-72 [15626919.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jan;24(1):39-55 [15626916.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):985-93 [12826891.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):391-400 [12352188.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):45-51 [14668550.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2455-9 [1933783.001]
  • [Cites] Hum Pathol. 1985 Jan;16(1):28-34 [2982713.001]
  • (PMID = 17393169.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Ljuca D, Fatusić Z, Iljazović E, Ahmetović B: Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. Bosn J Basic Med Sci; 2007 May;7(2):111-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
  • In about 70% of cases, ovarian carcinoma has been diagnosed at an advanced stage.
  • In that process, urokinase plasminogen activator (uPA) and its receptor, urokinase plasminogen activator receptor (suPAR) play a key role, that via plasmin activation lead to basal membrane and matrix degradation in surrounding of the tumor, enable to its invasion and metastasis.
  • Determination of serum concentration of those tumor markers can be useful in preoperative as well as in postoperative period.
  • Their serum concentrations in ovarian cancer patients may help in good monitoring of remission or progression during chemotherapy treatment.
  • In late 1950s and ear1y 1960s, when it was found out that malignant ovarian tumors were chemosensitive, their chemotherapy treatment has begun.
  • In the beginning it was used only mono-therapy, and by discovering new cytostatics it was replaced by poly-chemotherapy.
  • Now days, in the therapy of advanced stages of ovarian carcinoma combination of cisplatine or carboplatine with paclitaxel is considering as standard treatment.
  • Aim of this study was to determine serum uPA, suPAR and CEA in FIGO II and III patients with different histological type (serous, mucinous, clear cell tumor) before and after PT chemotherapy protocol during following three cycles.
  • In this prospective study we have analyzed 17 patients with ovarian carcinoma, those have been after surgery treated by chemotherapy.
  • Results of this study have shown that uPA, suPAR and CEA met criteria for prognostic markers for monitoring of successfulness of platina/taxol chemotherapy protocol for serous, mucinous and clear cell tumor FIGO II and III stage of ovarian carcinoma.
  • In case of PT chemotherapy protocol suPAR was better prognostic marker for monitoring of chemotherapy successfulness (Pearson coefficient 0,9 do 1,0; p<0,00l) than uPA (Pearson coefficient between 0,86 and 0,92; p<0,02) and CEA (Pearson coefficient 0,5 do 0,89; p<0,04).

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17489744.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; BG3F62OND5 / Carboplatin; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Helm CW, Randall-Whitis L, Martin RS 3rd, Metzinger DS, Gordinier ME, Parker LP, Edwards RP: Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol; 2007 Apr;105(1):90-6
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
  • OBJECTIVES: To review experience of secondary surgical cytoreduction (SSC) with hyperthermic intraperitoneal chemotherapy (IPHC).
  • METHODS: Eligible patients with ovarian cancer in whom pre-operative evaluation indicated that there was a good possibility that disease could be resected to < or = 5 mm underwent surgery followed by intraperitoneal perfusion of cisplatin (100 mg/m2) or mitomycin C (30-40 mg total dose) heated to 41-43 degrees C (105.8-109.4 degrees F) for 90 min.
  • Characteristics were median age 64 (37-77) years, mean prior laparotomies 1.4 (0-3), mean chemotherapy regimens 3.2 (0-7), mean time from initial therapy to IPHC 30.6 (1-88) months.
  • Original histology: papillary serous 12, poorly differentiated adenocarcinoma 1, serous low malignant potential 2, mucinous 1 and mixed subtypes 2.
  • 13 had recurrent disease and 5 had persistent disease following front-line therapy.
  • Mean time to return of bowel function was 7 (5-20) days and mean time to hospital discharge 11.5 (5-49) days.
  • All patients developed CTEP grade 1 or 2 metabolic or hematologic toxicities.
  • Improved outcome was significantly related to the size of residual disease prior to IPHC and postoperative chemotherapy.
  • CONCLUSIONS: IPHC is a relatively well-tolerated procedure with the majority of the morbidity being related to associated surgery.
  • When combined with SSC it has the potential to extend quality life in some patients with recurrent ovarian cancer and warrants continued research.
  • [MeSH-major] Hyperthermia, Induced / methods. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infusions, Parenteral. Middle Aged. Mitomycin / administration & dosage. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173957.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Chen AP, Zhang J, Liu H, Zhao SP, Dai SZ, Sun XL: [Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Jan;31(1):48-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma].
  • OBJECTIVE: To clarify the association of EGFR expression with angiogenesis and chemoresistance in ovarian cancer.
  • METHODS: Immunohistochemical PV-6000 staining was used to detect the expression of EGFR, LRP protein and MVD in 102 ovarian tumor specimens.
  • RESULTS: EGFR, LRP positive rates and MVD in borderline and malignant ovarian specimens were significantly higher than those in the normal and benign ones (P < 0.01).
  • EGFR positive expression rate in stage III-IV carcinoma tissues, poor differentiation and with ascites was higher than that in stage I-II carcinomas of well differentiation and without ascites (P < 0.05).
  • MVD was related to histological grade, residual tumor and ascites, LRP positive expression had no correlation with the clinicopathologic parameters (P > 0.05).
  • The effective rate of chemotherapy in patients with EGFR and LRP-positive expression were 57.1% and 53.7%, respectively, significantly lower than that in cases with EGFR and LRP-negative expression (85.0% and 90.9%, P < 0.05).
  • The survival time was shorter in the cases with EGFR and LRP-positive expression, poor differentiation, ascites and chemoresistance (P < 0.01), and only LRP-positive expression and chemotherapeutic effect were independently related to survival time (P < 0.05).
  • CONCLUSION: The expression of EGFR in ovarian cancer is related to angiogenesis and chemoresistance.
  • EGFR and LRP-positive expression are related to chemoresistance, and detection of the two proteins may be helpful in guiding chemotherapy choice for ovarian cancer.
  • [MeSH-major] Drug Resistance, Neoplasm. Neovascularization, Pathologic / pathology. Ovarian Neoplasms / blood supply. Receptor, Epidermal Growth Factor / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Antigens, CD34 / metabolism. Ascites / pathology. Cystadenocarcinoma, Mucinous / blood supply. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / blood supply. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Mucinous / blood supply. Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / blood supply. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Drug Resistance, Multiple. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538870.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


16. Iervolino P, Palmieri M, Rotondi M, D'Alessandro P, Iuliano R: [Borderline ovarian tumors. Retrospective analysis of 20 cases]. Minerva Ginecol; 2001 Feb;53(1 Suppl 1):97-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Borderline ovarian tumors. Retrospective analysis of 20 cases].
  • BACKGROUND: To evaluate the clinical features, the surgical management and outcome of 20 patients with stage-I borderline ovarian tumors.
  • METHODS: Twenty cases of FIGO stage-I ovarian tumors, aged from 31 to 58 years (mean 37 years) have been reviewed.
  • Minimal requirements for conservative management were adequate staging and complete information about the therapeutic options.
  • Factors important in the choice of the treatment were, age, wish to preserve fertility, histologic type and grade, and the stage of the tumour.
  • Thirteen (65%) were with mucinous cystadenoma of borderline malignancy, 7 cases (35%) were of serous type.
  • One patient underwent enucleation of ovarian tumor and biopsy of contralateral ovary.
  • Any patient were treated with chemotherapy after operation.
  • CONCLUSIONS: Conservative surgery remains a therapeutic option in selected patients with borderline ovarian tumors.
  • Prolonged intensive follow-up is required for women treated conservatively for borderline malignant ovarian tumours.
  • [MeSH-major] Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11526732.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Muzii L, Palaia I, Sansone M, Calcagno M, Plotti F, Angioli R, Panici PB: Laparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies. Fertil Steril; 2009 Jun;91(6):2632-7
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies.
  • OBJECTIVE: To assess feasibility and safety of fertility-sparing laparoscopic staging in women affected by unexpected ovarian cancer desiring to preserve their fertility.
  • PATIENT(S): Twenty-seven patients already operated on elsewhere for a presumably benign ovarian cyst.
  • RESULT(S): Histologic findings after first surgery: 12 low malignant potential neoplasms, 11 invasive epithelial ovarian carcinomas,1 sex-cord stromal, and 3 germ cell neoplasms.
  • Fertility-sparing staging consisted of exploration of the peritoneal cavity, peritoneal washing cytology, multiple peritoneal biopsies, omolateral adnexectomy (except in borderline tumors), omentectomy, omolateral or bilateral pelvic and aortic lymph node sampling (except in borderline tumors, well differentiated, mucinous, and granulosa cell (GC) neoplasms), endometrial biopsy, appendectomy in mucinous type.
  • Six patients received adjuvant platinum-based chemotherapy.
  • CONCLUSION(S): Laparoscopic fertility-sparing staging in early ovarian malignancies is feasible and safe in selected and counseled patients and should be performed in experienced gynecological oncology centers trained in endoscopic procedures.
  • [MeSH-major] Fertility / physiology. Laparoscopy / methods. Ovarian Cysts / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Counseling. Cystectomy. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging. Ovariectomy. Prospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555237.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP: In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol; 2004 Jan;92(1):160-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
  • OBJECTIVES: To determine whether there is a relationship between histologic subtype of epithelial ovarian cancer and chemoresistance, we evaluated ovarian carcinomas of six histologic subtypes and correlated histology with in vitro drug response.
  • METHODS: In vitro drug response profiles for different histologic subsets of epithelial ovarian carcinomas exposed to standard relevant chemotherapy agents were determined in the Extreme Drug Resistance assay (EDR).
  • RESULTS: Of 5195 referred serial cases of epithelial ovarian cancer, there were 2660 papillary serous, 303 endometrioid, 142 mucinous, 102 clear cell, 952 undifferentiated carcinomas, and 42 tumors of low malignant potential.
  • For the samples as a whole, the incidences of extreme drug resistance to the tested chemotherapeutic agents were cisplatin 10%, carboplatin 16%, cyclophosphamide 16%, doxorubicin 40%, gemcitabine 21%, paclitaxel 22%, and topotecan 13%.
  • When compared to papillary serous tumors, mucinous tumors were more frequently resistant to cisplatin (10% vs. 18%) but less frequently resistant to topotecan (13% vs. 5%) and doxorubicin (42% vs. 16%).
  • CONCLUSIONS: We found significant differences in the frequencies of extreme drug resistance to chemotherapeutic agents and biomarker expression among histologic subtypes of epithelial ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Drug Resistance, Multiple. Ovarian Neoplasms / classification
  • [MeSH-minor] Drug Resistance, Neoplasm. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis


19. Milojkovic M, Hrgovic Z, Hrgovic I, Jonat W, Maass N, Buković D: Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis. Arch Gynecol Obstet; 2004 Mar;269(3):176-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
  • AIM: Our aim was to confirm that preoperative CA 125 serum level can be useful for discrimination between benign and malignant masses in the pelvis.
  • METHODS: Preoperative CA 125 serum level was analyzed retrospectively in 121 patients who had surgery because of a malignant ovarian tumor and in 91 patients with benign masses in the pelvis.
  • The cutoff serum level CA 125 between benign and malignant masses in the pelvis was 35 and 65 IU/ml.
  • RESULTS: Of those patients with a malignant ovarian tumor, 65.3% had menopause whereas only 31.5% of those with a benign tumor did so.
  • The average age of the patients with a malignant tumor was 54.2 years and of those with a benign tumor 46.8 years.
  • The preoperative CA 125 serum level was higher than 35 IU/ml in 80.2% and higher than 65 IU/ml in 72.7% of all analyzed patients with a malignant tumor, whereas it was 23.9% and 9.8% respectively in patients with a benign mass.
  • In early stage ovarian cancer disease (borderline stage, I/II) the preoperative CA 125 serum level was higher than 35 IU/ml in 67.8% and in 52.5% higher than 65 IU/ml.
  • After therapy the CA 125 serum level dropped below 35 IU/ml in 70.8% and after three chemotherapy courses in 78.1%.
  • A CA 125 level less than 35 IU/ml was achieved by therapy in 84.2% patients with an early stage disease (I/II) and in 62.1% in advanced stages (III/IV).
  • CONCLUSION: . Preoperative determination of CA 125 is a very useful method to discriminate between benign and malignant masses in the pelvis.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Genital Diseases, Female / blood
  • [MeSH-minor] Cystadenocarcinoma, Mucinous / blood. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / blood. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Predictive Value of Tests. Preoperative Care. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14557888.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


20. Papathanasiou K, Tolikas A, Dovas D, Kostopoulou E, Fragkedakis N, Tzafettas J: Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1191-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology.
  • A case of a mucinous adenocarcinoma of the ovary with a synchronous endometroid tumor of the endometrium with focal features of undifferentiated carcinoma and deep myometrial invasion is reported.
  • A review of the literature revealed that our case is interesting in view of the fact that simultaneous presentation of primary ovarian and endometrial neoplasms is rare and usually related to low-stage ovarian lesions and well-differentiated and superficial endometrial carcinomas in contrast to our case with the focal features of undifferentiated carcinoma and the deep myometrial invasion.
  • The prognosis in most of the cases is surprisingly good even after total abdominal hysterectomy and bilateral oophorectomy alone without adjuvant chemotherapy or irradiation.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343211.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Wong HF, Low JJ, Chua Y, Busmanis I, Tay EH, Ho TH: Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer; 2007 Mar-Apr;17(2):342-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004.
  • Borderline ovarian tumors account for 15% of epithelial ovarian cancers and are different from invasive malignant carcinoma.
  • Histological origin was as follows: mucinous (68%), serous (26%), endometrioid (2.6%), and clear cell (1.2%).
  • Primary surgical procedures undertaken were as follows: hysterectomy with bilateral salpingo-oophorectomy (52%), unilateral salpingo-oophorectomy (33%), or ovarian cystectomy (15%).
  • Adjuvant chemotherapy was administered in 13 patients (5.2% of cases), of which 4 patients were given chemotherapy only because of synchronous malignancies.
  • Overall mean time to recurrence was 59 months.
  • There were a total of five deaths (2.8%): three (1.5%) from invasive ovarian/peritoneal carcinoma and two from synchronous uterine malignancies.
  • It appears that surgical resection is the mainstay of treatment, with conservative surgery where fertility is desired or pelvic clearance if the family is complete.
  • The role of adjuvant chemotherapy is not established.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Frozen Sections. Humans. Middle Aged. Neoplasm Staging. Recurrence. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343573.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Li M, Pan LY, Huang HF, Lang JH: [Epithelial ovarian tumors in adolescence: a study of clinical features and treatment]. Zhonghua Fu Chan Ke Za Zhi; 2004 Sep;39(9):598-601
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelial ovarian tumors in adolescence: a study of clinical features and treatment].
  • OBJECTIVE: To study the clinical feature, diagnosis and treatment of epithelial ovarian tumors in adolescent patients.
  • METHODS: A retrospective analysis was performed on 29 patients of epithelial ovarian tumors between the age of 13 and 19 during the period of 1983 - 2002 in Peking Union Medical College Hospital.
  • Twenty of the cases were with benign tumors, four with borderline, and five with malignant tumors.
  • The histological types included mucinous tumor in twenty-two cases, serous tumor in six, and endometroid tumor in one case.
  • Among the nine cases with borderline or malignant tumors, eight were at stage I and one at stage IIIc.
  • Of benign tumor group, an abdominal unilateral salpingo-oophorectomy was performed on nine cases.
  • The nine cases with borderline or malignant tumors underwent cytoreductive surgery and comprehensive staging surgery; fertility was preserved for eight of them.
  • A cisplatin combined chemotherapy was given to four patients with malignant tumors.
  • CONCLUSIONS: The incidence of epithelial ovarian tumors during adolescence increases with age.
  • Mucinous tumor is the most common histological type in adolescent patients.
  • The therapeutic strategy should be individualized, and surgical approach should consider both cure and preservation of fertility in malignant cases.
  • [MeSH-major] Carcinoma / therapy. Ovarian Neoplasms / therapy. Puberty
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Laparoscopy. Neoplasm Staging. Ovary / surgery. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15498186.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • In 2 cases, the tumor was associated with a mature cystic teratoma; one of them also containing an invasive moderately differentiated adenocarcinoma.
  • A single case was associated with a benign ovarian cyst.
  • NSCNEC represented anywhere from 10% to 90% of the ovarian tumor.
  • Seven patients were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy.
  • One patient had a bilateral salpingo-oophorectomy with omentectomy and appendectomy followed by chemotherapy; 1 patient had a total abdominal hysterectomy with right salpingo-oophorectomy followed by chemotherapy; one had a bilateral salpingo-oophorectomy followed by chemotherapy, and one had a right salpingo-oophorectomy with appendectomy followed by chemotherapy.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


24. Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y: The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study. Int J Gynecol Cancer; 2009 Nov;19(8):1353-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study.
  • Pure-type clear cell carcinoma (CCC) has been recognized as a distinct subtype of ovarian cancer, showing resistance to conventional platinum-based chemotherapy and resulting in poor prognosis.
  • Our study implied that complete surgical staging enabled us to distinguish a high-risk group of recurrence in pT1 M0 CCC; however, the procedure could not improve OS.
  • Although the study was a limited retrospective study, the impact of peritoneal cytology status was more important than complete surgical staging procedure in CCC patients.
  • More effective treatment modality was warranted, especially for CCC cases positive for malignant peritoneal cytology.
  • [MeSH-major] Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / surgery. Ovarian Neoplasms / mortality. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Antineoplastic Agents / therapeutic use. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009889.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Song TF, Zhang ZF, Liu L, Yang T, Jiang J, Li P: Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910). J Int Med Res; 2009 Sep-Oct;37(5):1375-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).
  • Immunohistochemical staining for HSP27 in human ovarian cancer specimens showed HSP27 was associated with aggressive malignant ovarian disease.
  • Small interfering RNA (siRNA) was used to down-regulate HSP27 in human ovarian cancer cells (HO8910).
  • The siRNA-induced knock-down of HSP27 could be a novel and potent strategy to help overcome chemotherapeutic resistance to paclitaxel in epithelial ovarian cancer cells.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Drug Resistance, Neoplasm / drug effects. HSP27 Heat-Shock Proteins / genetics. Ovarian Neoplasms / drug therapy. Paclitaxel / pharmacology. RNA, Small Interfering / pharmacology. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / secondary. Apoptosis. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / genetics. Endometrial Neoplasms / secondary. Female. Gene Silencing. Humans. Immunoenzyme Techniques. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19930842.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Reactive Oxygen Species; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group: Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol; 2008 Jan 1;26(1):83-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
  • PURPOSE: To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC).
  • RESULTS: The median PFS and OS for this group of stage IV ovarian cancer patients was 12 and 29 months, respectively.
  • Multivariate regression analysis revealed that histology, malignant pleural effusion, intraparenchymal liver metastasis, and residual tumor size were significant prognostic variables.
  • Patients with less than 5.0 cm of disease initially and significant disease and/or comorbidities precluding microscopic cytoreduction may be considered for alternative therapeutic options other than primary cytoreduction.
  • [MeSH-major] Neoplasm, Residual / etiology. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cisplatin / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Follow-Up Studies. Humans. Medical Records. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pleural Effusion, Malignant / etiology. Postoperative Complications / etiology. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Apr 1;26(10):1771-2; author reply 1772 [18375912.001]
  • (PMID = 18025437.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Beyrouti MI, Beyrouti R, Frikha F, Ben Amar M, Abid M, Ben Ameur H, Ben Salah K, Guirat A, Boujelben S: [Peritoneal gelatinous ascites]. Presse Med; 2007 Jul-Aug;36(7-8):1141-7
Genetic Alliance. consumer health - Gelatinous Ascites.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It most often follows a mucinous tumor of the appendix.
  • An ovarian origin in woman has been suggested but remains controversial.
  • Ultrasonography and computed tomography provide complementary signs: septa and scalloping of the liver margins, respectively.
  • Recurrence is more frequent in the forms associated with malignant or bipolar tumors.
  • Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is the only therapy shown to be effective in cases of recurrence or malignant forms.
  • [MeSH-major] Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / diagnosis. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Appendectomy. Biopsy, Needle. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Hyperthermia, Induced. Laparotomy. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / therapy. Paracentesis. Preoperative Care. Rare Diseases. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603922.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


28. Tannuri AC, Tannuri U, Gibelli NE, Romão RL: Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation. J Pediatr Surg; 2009 Nov;44(11):2083-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation.
  • Ultrasonography, computed tomographic (CT) scan, and needle biopsy were the initial methods used to diagnose malignant tumors.
  • After neoadjuvant chemotherapy, tumor resectability was evaluated by another CT scan.
  • RESULTS: Fifty-three children with hepatic tumors underwent surgical treatment, 47 patients underwent liver resections, and in 6 cases, liver transplantation was performed because the tumor was considered unresectable.
  • Ten children presented with other malignant tumors-3 undifferentiated sarcomas, 2 hepatocellular carcinomas, 2 fibrolamellar hepatocellular carcinomas, a rhabdomyosarcoma, an immature ovarian teratoma, and a single neuroblastoma.
  • Six children had benign tumors-4 mesenchymal hamartoma, 1 focal nodular hyperplasia, and a mucinous cystadenoma.
  • The overall mortality rate was 14.9%, and all deaths were related to recurrence of malignant disease.
  • The mortality rate of hepatoblastoma patients was less than other malignant tumors (P = .04).
  • [MeSH-minor] Age Factors. Blood Loss, Surgical. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Follow-Up Studies. Hepatectomy / methods. Hepatoblastoma / mortality. Hepatoblastoma / surgery. Humans. Infant. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19944212.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement